In Q4'25, Eli Lilly's (LLY) operating cash flow reached $3.22B USD, reflecting a robust quarter driven by strong operational performance, while free cash flow stood at $678M USD, indicating solid liquidity after capital expenditures. This latest data point marks a sequential decline from the exceptional Q3'25 operating cash flow of $8.84B USD but remains positive year-over-year. Over the period from Q1'23 to Q4'25, operating cash flow exhibited significant volatility, starting at $1.73B USD in Q1'23, dipping to a negative -$312M USD in Q4'23, and surging to a peak of $8.84B USD in Q3'25 amid accelerating growth trends likely tied to product demand. Free cash flow followed a similar volatile pattern, with early negatives like -$1.38B USD in Q4'23 giving way to strong positives, peaking at $6.75B USD in Q3'25, highlighting improving capital efficiency and overall cash generation momentum in recent quarters despite occasional dips.